The number that matters is the comparison. A course of TMS brings meaningful improvement in about half of treatment-resistant patients and full remission in roughly one in three 1. On its own that sounds modest. Set against the medication ladder it isn't: after three failed antidepressants, the next pill's remission odds are about one in seven 2.
It is mainstream, not experimental. FDA-cleared since 2008 3, Medicare and major insurers cover it, and the Canadian, European, and US guidelines all list it as a recommended step once antidepressants fail 4, 5. The Canadian guideline puts it first-line after a single medication failure.
The side-effect profile is the quiet selling point. No memory loss, no sedation, no weight gain, no sexual side effects. About a third get scalp discomfort or a headache the first week, and it settles. Serious seizure risk runs about one per 30,000 sessions, almost always in someone with a known risk factor 6.
The move here is asking for a referral, then knowing what you're signing up for.
The arc is slow, then sudden.
- First ten sessions: nothing, maybe a headache the first week. You sit, you tap, you go home.
- Week three or four: for responders, the wet-blanket feeling lifts first. Getting out of bed stops being a negotiation before anything feels like joy.
- Week six: if it landed, people start saying you seem like yourself again. A third get this fully, a quarter partially, the rest don't 1.
- Months to years: the benefit holds for most responders, sometimes drifting back.
The fine print — when to skip it, and what people get wrong
TMS is not ECT. ECT needs anesthesia, induces a seizure, and carries real memory cost; TMS stays below seizure threshold and has no cognitive side effects 8. You're awake and drive home. The new five-day accelerated protocol is promising but came from under thirty patients and isn't yet standard 9.
The common failure is stopping early. Better outcomes track completing the full 30-plus sessions, so feeling better at session sixteen is the moment to push through 1. And about half of responders relapse within a year without maintenance, so plan on boosters and a low threshold for re-induction 10.
- 1Carpenter LL et al. (2012). Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of acute treatment outcomes in clinical practice. Depression and Anxiety. link
- 2Rush AJ et al. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. American Journal of Psychiatry. link
- 3FDA (2008). FDA clearance K061053: NeuroStar TMS Therapy System for major depressive disorder. link
- 4Milev RV et al. (2016). Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 4. Neurostimulation Treatments. Canadian Journal of Psychiatry. link
- 5Lefaucheur JP et al. (2020). Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): an update (2014-2018). Clinical Neurophysiology. link
- 6Rossi S et al. (2021). Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: expert guidelines. Clinical Neurophysiology. link
- 7Blumberger DM et al. (2018). Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. The Lancet. link
- 8Mutz J et al. (2019). Comparative efficacy and acceptability of non-surgical brain stimulation for the acute treatment of major depressive episodes in adults: systematic review and network meta-analysis. BMJ. link
- 9Cole EJ et al. (2022). Stanford Neuromodulation Therapy (SNT): a double-blind randomized controlled trial. American Journal of Psychiatry. link
- 10Dunner DL et al. (2014). A multisite, naturalistic, observational study of transcranial magnetic stimulation for patients with pharmacoresistant major depressive disorder: durability of benefit over a 1-year follow-up period. Journal of Clinical Psychiatry. link
დაკავშირებული სახელმძღვანელოში (4)
- — TMS is FDA-cleared for quitting smoking too, aiming pulses at the addiction circuit, though few clinics actually offer it.
- — Exercise is for everyday depression; TMS is the escalation when pills and lifestyle haven't shifted a treatment-resistant case.
- — Ketamine works in hours where TMS takes weeks of daily visits — both are options once standard antidepressants fail.
- — TMS is for depression that hasn't budged on therapy and pills — it's an escalation, not a replacement for trying them first.
ტრანსკრანიალური მაგნიტური სტიმულაცია (TMS)
ამ სტატიის არსებობის მიზეზი. დაახლოებით ყოველი მესამე მკურნალობარეზისტენტული პაციენტი რემისიას აღწევს — თვისობრივად განსხვავებული „კიდევ ერთი აბის მოსინჯვისგან, რომელიც ვერ იმუშავებს".
მრავალი ცრუ-კონტროლირებადი კვლევა, FDA-ს მიერ დამტკიცებული სამი მდგომარეობისთვის, წამყვანი სახელმძღვანელოები მხარს უჭერენ. დამკვიდრებული მედიცინა და არა ექსპერიმენტული.
პაციენტისთვის, რომელიც რეაგირებს, ყოველდღიური ფუნქცია ექვს კვირაში ბრუნდება — ენერგია ბრუნდება, წვრილმანები წყვეტს შეუძლებლად ყოფნას.
ფასი $10,000+-ია დეპრესიის კურსისთვის. დაზღვევა მკურნალობარეზისტენტული დეპრესიისთვის ფარავს მას ამერიკის უმეტეს გეგმაში, ამიტომ პაციენტების უმეტესობა მხოლოდ თანაგადახდებს იხდის.
ყოველდღიური ვიზიტები კლინიკაში, სამუშაო დღეებში, ოთხიდან ექვს კვირამდე. სავარძელში დრო მოკლეა; რეალური ხარჯი გრაფიკია.
განწყობის ამაღლებასთან ერთად დეპრესიის უფერული გადაღლაც ქრება. სტიმულატორი არ არის — უფრო „აღარაფერი გითრევს ქვევით"-ს ჰგავს.
დეპრესიის გაწმენდასთან ერთად აზროვნება იმახვილდება. კოგნიტური გვერდითი ეფექტებიც არ აქვს — ECT-სგან განსხვავებით, შენი მეხსიერება ხელუხლებელი რჩება.